FDA Approves Arikayce (amikacin liposome inhalation suspension) to treat Mycobacterium Avium Complex (MAC) Lung Disease
September 28, 2018 -- The U.S. Food and Drug Administration today approved a new drug, Arikayce (amikacin liposome inhalation suspension), for the treatment of lung disease caused by a group of bacteria, Mycobacterium avium complex (MAC) in a...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Drugs & Pharmacology | Food and Drug Administration (FDA)